DK1104306T3 - Præparater af CpG- og saponinadjuvanser og fremgangsmåder til anvendelse deraf - Google Patents

Præparater af CpG- og saponinadjuvanser og fremgangsmåder til anvendelse deraf

Info

Publication number: DK1104306T3
Authority: DK; Denmark
Prior art keywords: methods; saponin adjuvants; cpg; preparations; immunostimulatory oligonucleotides
Prior art date: 1998-08-10

Application number

DK99939711T

Other languages

English (en)

Inventor

Charlotte A Kensil

Original Assignee

Antigenics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-08-10

Filing date

1999-08-06

Publication date

2006-05-22

1999-08-06 Application filed by Antigenics Inc filed Critical Antigenics Inc

2006-05-22 Application granted granted Critical

2006-05-22 Publication of DK1104306T3 publication Critical patent/DK1104306T3/da

Links

239000002671 adjuvant Substances 0.000 title abstract 4
239000001397 quillaja saponaria molina bark Substances 0.000 title abstract 3
229930182490 saponin Natural products 0.000 title abstract 3
150000007949 saponins Chemical class 0.000 title abstract 3
238000000034 method Methods 0.000 title abstract 2
238000002360 preparation method Methods 0.000 title 1
108091034117 Oligonucleotide Proteins 0.000 abstract 2
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 2
230000002708 enhancing effect Effects 0.000 abstract 2
230000003308 immunostimulating effect Effects 0.000 abstract 2
239000000203 mixture Substances 0.000 abstract 2
230000024932 T cell mediated immunity Effects 0.000 abstract 1
239000000427 antigen Substances 0.000 abstract 1
102000036639 antigens Human genes 0.000 abstract 1
108091007433 antigens Proteins 0.000 abstract 1
230000028993 immune response Effects 0.000 abstract 1
230000036039 immunity Effects 0.000 abstract 1
230000016784 immunoglobulin production Effects 0.000 abstract 1
230000004936 stimulating effect Effects 0.000 abstract 1
229960005486 vaccine Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Mycology (AREA)
Microbiology (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Steroid Compounds (AREA)

DK99939711T 1998-08-10 1999-08-06 Præparater af CpG- og saponinadjuvanser og fremgangsmåder til anvendelse deraf DK1104306T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US9591398P	1998-08-10	1998-08-10
US12860899P	1999-04-08	1999-04-08

Publications (1)

Publication Number	Publication Date
DK1104306T3 true DK1104306T3 (da)	2006-05-22

Family

ID=26790746

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK99939711T DK1104306T3 (da)	1998-08-10	1999-08-06	Præparater af CpG- og saponinadjuvanser og fremgangsmåder til anvendelse deraf

Country Status (11)

Country	Link
US (2)	US7049302B1 (da)
EP (1)	EP1104306B1 (da)
JP (1)	JP4620251B2 (da)
AT (1)	ATE315405T1 (da)
AU (1)	AU773204C (da)
CA (1)	CA2340174C (da)
DE (1)	DE69929444T2 (da)
DK (1)	DK1104306T3 (da)
ES (1)	ES2257068T3 (da)
PT (1)	PT1104306E (da)
WO (1)	WO2000009159A1 (da)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6207646B1 (en)	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US20030026782A1 (en)	1995-02-07	2003-02-06	Arthur M. Krieg	Immunomodulatory oligonucleotides
US6406705B1 (en)	1997-03-10	2002-06-18	University Of Iowa Research Foundation	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6589940B1 (en)	1997-06-06	2003-07-08	Dynavax Technologies Corporation	Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US20020147143A1 (en)	1998-03-18	2002-10-10	Corixa Corporation	Compositions and methods for the therapy and diagnosis of lung cancer
DK1733735T3 (da)	1998-05-22	2017-06-19	Ottawa Hospital Res Inst	Fremgangsmåder og produkter til induktion af mukosal immunitet
EP1104306B1 (en) *	1998-08-10	2006-01-11	Antigenics Inc.	Compositions of cpg and saponin adjuvants and methods of use thereof
US20030235557A1 (en)	1998-09-30	2003-12-25	Corixa Corporation	Compositions and methods for WT1 specific immunotherapy
ES2572834T3 (es) *	1999-02-17	2016-06-02	Csl Limited	Complejos inmunogénicos y métodos relacionados con los mismos
GB9908885D0 (en) *	1999-04-19	1999-06-16	Smithkline Beecham Biolog	Vccine
CN1227030C (zh) *	1999-04-19	2005-11-16	史密丝克莱恩比彻姆生物有限公司	包含皂甙和免疫刺激寡核苷酸的佐剂组合物
US6558670B1 (en)	1999-04-19	2003-05-06	Smithkline Beechman Biologicals S.A.	Vaccine adjuvants
ES2311478T3 (es) *	1999-11-19	2009-02-16	Csl Limited	Composiciones de vacuna contra el hcv.
WO2001051083A2 (en) *	2000-01-13	2001-07-19	Antigenics Inc.	Innate immunity-stimulating compositions of cpg and saponin and methods thereof
CN1254541C (zh)	2000-02-23	2006-05-03	史密丝克莱恩比彻姆生物有限公司	新化合物
DE60139963D1 (de)	2000-06-20	2009-10-29	Corixa Corp	Fusionsproteine aus mycobakterium tuberculosis
EP1319069B1 (en)	2000-06-28	2008-05-21	Corixa Corporation	Compositions and methods for the therapy and diagnosis of lung cancer
UA79735C2 (uk)	2000-08-10	2007-07-25	Глаксосмітклайн Байолоджікалз С.А.	Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
HU229642B1 (en) *	2000-10-18	2014-03-28	Glaxosmithkline Beecham Biolog S A	Vaccines against cancers
DK1889630T3 (da) *	2000-10-18	2012-03-05	Glaxosmithkline Biolog Sa	Vacciner omfattende MAGE-antigen koblet til protein D-fragment
CA2446788A1 (en)	2001-05-09	2002-11-14	Corixa Corporation	Compositions and methods for the therapy and diagnosis of prostate cancer
EP1450856B1 (en)	2001-09-14	2009-11-11	Cytos Biotechnology AG	Packaging of immunostimulatory cpg into virus-like particles: method of preparation and use
EP1581119B1 (en)	2001-12-17	2013-01-30	Corixa Corporation	Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
US20060210555A1 (en) *	2001-12-21	2006-09-21	Antigenics, Inc.	Compositions comprising immunoreactive reagents and saponins, and methods of use thereof
BR0311995A (pt) *	2002-06-20	2005-04-05	Cytos Biotechnology Ag	Partìculas semelhantes a vìrus empacotadas para o uso como adjuvantes: método de preparação e uso
JP2005532405A (ja) *	2002-07-10	2005-10-27	アクゾ・ノベル・エヌ・ベー	融合タンパク質とサポニンアジュバントとを含む免疫原性組成物
JP2006512927A (ja)	2002-12-11	2006-04-20	コーリーファーマシューティカルグループ，インコーポレイテッド	５’ｃｐｇ核酸およびその使用方法
EP1608403A2 (en) *	2003-04-02	2005-12-28	Coley Pharmaceutical Group, Ltd.	Immunostimulatory nucleic acid oil-in-water formulations for topical application
AU2004308964B2 (en)	2003-12-23	2010-09-16	Arbor Vita Corporation	Antibodies for oncogenic strains of HPV and methods of their use
WO2005072290A2 (en) *	2004-01-23	2005-08-11	Joslin Diabetes Center	Methods of treating, reducing, or preventing autoimmune conditions
DE602005025342D1 (de)	2004-05-28	2011-01-27	Glaxosmithkline Biolog Sa	Impfstoffzusammensetzungen mit virosomen und einem saponin-adjuvans
BRPI0609547A2 (pt)	2005-03-31	2011-10-18	Glaxosmithkline Biolog Sa	composição, uso de uma composição, método para o tratamento ou prevenção de infecção por chlamydia, uso de uma ou mais proteìnas de chlamydia, de fragmentos imunogênicos das mesmas ou de polinucleotìdeos codificando os mesmos, método para o tratamento ou prevenção de infecção por chlamydia, e, método para a determinação prévia de infecção por chlamydia em um indivìduo
TW200817680A (en)	2006-06-02	2008-04-16	Glaxosmithkline Biolog Sa	Method
WO2008057529A2 (en) *	2006-11-06	2008-05-15	Coley Pharmaceutical Group, Inc.	Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (cetp)
BRPI0809926B8 (pt)	2007-04-04	2021-05-25	Infectious Disease Res Inst	composição que compreende antígenos de mycobacterium tuberculosis, polipeptídeo de fusão isolado, polinucleotídeo isolado que codifica o dito polipeptídeo e uso da dita composição para estimular uma resposta imune protetora
US8518903B2 (en)	2007-04-19	2013-08-27	University of Pittsburgh—of the Commonwealth System of Higher Education	Use of toll-like receptor-9 agonists
WO2008131074A1 (en)	2007-04-19	2008-10-30	University Of Pittsburgh - Of The Commonwealth System Of Higher Education	Use of toll-like receptor-9 agonists, toll-like receptor-4 antagonists, and/or nuclear oligomerization domain-2 agonists for the treatment or prevention of toll-like receptor-4-associated disorders
KR101238795B1 (ko) *	2007-05-24	2013-03-07	글락소스미스클라인 바이오로지칼즈 에스.에이.	동결건조 항원 조성물
CA2699856C (en)	2007-09-17	2019-08-20	Oncomethylome Sciences Sa	Improved methylation detection
WO2009156960A2 (en)	2008-06-27	2009-12-30	Pfizer Inc.	Novel adjuvant compositions
TW201010719A (en) *	2008-08-19	2010-03-16	Wyeth Corp	Immunological composition
SG171914A1 (en)	2008-12-02	2011-07-28	Chiralgen Ltd	Method for the synthesis of phosphorus atom modified nucleic acids
EP2202298A1 (en)	2008-12-23	2010-06-30	Stichting Dienst Landbouwkundig Onderzoek	Recombinant classical swine fever virus (CSFV) comprising a modified E2 protein and methods for generating said recombinant CSFV
TWI389694B (zh) *	2008-12-23	2013-03-21	Intervet Int Bv	皂素或皂素與CpG之組合於誘發針對腫瘤特異性自體抗原之免疫反應之用途
EP2408933A2 (en)	2009-03-17	2012-01-25	MDxHealth SA	Improved detection of gene expression
EP2451461A4 (en)	2009-07-06	2013-05-29	Ontorii Inc	NOVEL NUCLEIC ACID PRODRUGS AND METHOD OF USE THEREOF
GB0917457D0 (en)	2009-10-06	2009-11-18	Glaxosmithkline Biolog Sa	Method
EP2575878B1 (en)	2010-05-28	2018-06-13	Zoetis Belgium S.A.	Vaccines comprising cholesterol and cpg as sole adjuvant-carrier molecules
US9072760B2 (en)	2010-09-24	2015-07-07	University of Pittsburgh—of the Commonwealth System of Higher Education	TLR4 inhibitors for the treatment of human infectious and inflammatory disorders
US10668092B2 (en)	2010-09-24	2020-06-02	The John Hopkins University	Compositions and methods for treatment of inflammatory disorders
DK2620428T3 (da)	2010-09-24	2019-07-01	Wave Life Sciences Ltd	Asymmetrisk hjælpegruppe
WO2012057904A1 (en)	2010-10-27	2012-05-03	Infectious Disease Research Institute	Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
EP2637687B1 (en)	2010-11-08	2021-01-06	Infectious Disease Research Institute	Vaccines comprising non-specific nucleoside hydrolase and sterol 24-c-methyltransferase (smt) polypeptides for the treatment and diagnosis of leishmaniasis
WO2012088425A2 (en)	2010-12-22	2012-06-28	University Of Pittsburgh - Of The Commonwealth System Of Higher Education	Gap junction-enhancing agents for treatment of necrotizing enterocolitis and inflammatory bowel disease
GB201106357D0 (en)	2011-04-14	2011-06-01	Pessi Antonello	Composition and uses thereof
CN103608030A (zh)	2011-06-21	2014-02-26	昂科发克特公司	用于治疗和诊断癌症的组合物和方法
US9605019B2 (en)	2011-07-19	2017-03-28	Wave Life Sciences Ltd.	Methods for the synthesis of functionalized nucleic acids
CN112007045B (zh)	2012-07-13	2026-01-06	波涛生命科学有限公司	手性控制
DK2872485T3 (da)	2012-07-13	2021-03-08	Wave Life Sciences Ltd	Asymmetrisk hjælpegruppe
MX385774B (es)	2012-08-03	2025-03-18	Infectious Disease Res Inst	Composiciones para usarse en el tratamiento de una infección activa por mycobacterium tuberculosis.
WO2014052453A1 (en)	2012-09-25	2014-04-03	University Of Pittsburgh - Of The Commonwealth System Of Higher Education	Oral therapy of necrotizing enterocolitis
WO2014160987A2 (en)	2013-03-28	2014-10-02	Infectious Disease Research Institute	Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis
UA121200C2 (uk)	2013-09-19	2020-04-27	Зоетіс Сервісіз Ллс	Ад'ювант на основі олії
WO2015108048A1 (ja) *	2014-01-15	2015-07-23	株式会社新日本科学	抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
EP3095461A4 (en) *	2014-01-15	2017-08-23	Shin Nippon Biomedical Laboratories, Ltd.	Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
US10322173B2 (en)	2014-01-15	2019-06-18	Shin Nippon Biomedical Laboratories, Ltd.	Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
KR102423317B1 (ko)	2014-01-16	2022-07-22	웨이브 라이프 사이언시스 리미티드	키랄 디자인
DK3148579T3 (da)	2014-05-28	2021-03-08	Agenus Inc	Anti-gitr antistoffer og fremgangsmåder til anvendelse deraf
AR102547A1 (es)	2014-11-07	2017-03-08	Takeda Vaccines Inc	Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
AR102548A1 (es)	2014-11-07	2017-03-08	Takeda Vaccines Inc	Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y uso
EP4248992A3 (en)	2015-01-16	2023-12-27	Zoetis Services LLC	Foot-and-mouth disease vaccine
CN107249629A (zh) *	2015-02-26	2017-10-13	生控基因疫苗股份有限公司	包含免疫原性蛋白质及组合佐剂并用以诱发抗原特异性t细胞反应的疫苗组合物
EP3294324A1 (en)	2015-05-13	2018-03-21	Agenus Inc.	Vaccines for treatment and prevention of cancer
WO2016191553A1 (en)	2015-05-26	2016-12-01	Ohio State Innovation Foundation	Nanoparticle based vaccine strategy against swine influenza virus
US10456459B2 (en)	2015-07-20	2019-10-29	Zoetis Services Llc	Liposomal adjuvant compositions
EP3344656A1 (en)	2015-09-01	2018-07-11	Agenus Inc.	Anti-pd-1 antibodies and methods of use thereof
SG10201912984WA (en)	2015-12-02	2020-03-30	Agenus Inc	Antibodies and methods of use thereof
MX2018014270A (es)	2016-05-21	2019-02-14	Infectious Disease Res Inst	Composiciones y metodos para tratar la tuberculosis secundaria e infecciones po micobacteria no tuberculosa.
MX389710B (es)	2016-05-27	2025-03-20	Agenus Inc	Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y métodos para usarlos.
CA3036218A1 (en)	2016-09-16	2018-03-22	Infectious Disease Research Institute	Vaccines comprising mycobacterium leprae polypeptides for the prevention, treatment, and diagnosis of leprosy
KR102576042B1 (ko)	2016-10-11	2023-09-07	아게누스 인코포레이티드	항-lag-3 항체 및 이의 사용 방법
AU2018207172B2 (en)	2017-01-13	2023-10-12	Mink Therapeutics, Inc.	T cell receptors that bind to NY-ESO-1 and methods of use thereof
JP7297672B2 (ja)	2017-04-13	2023-06-26	アジェナスインコーポレイテッド	抗ｃｄ１３７抗体およびその使用方法
RS64576B1 (sr)	2017-05-01	2023-10-31	Agenus Inc	Anti-tigit antitela i postupci njihove primene
WO2019035963A1 (en)	2017-08-16	2019-02-21	Ohio State Innovation Foundation	NANOPARTICLE COMPOSITIONS FOR VACCINES AGAINST SALMONELLA
CN107537035A (zh) *	2017-08-30	2018-01-05	北京恩元华生物科技有限公司	复合佐剂及含复合佐剂的狂犬疫苗及其制备方法和应用
JP7387585B2 (ja)	2017-09-04	2023-11-28	アジェナスインコーポレイテッド	混合系統白血病（ｍｌｌ）特異的ホスホペプチドに結合するｔ細胞受容体およびその使用方法
CA3081586A1 (en)	2017-11-03	2019-05-09	Takeda Vaccines, Inc.	Zika vaccines and immunogenic compositions, and methods of using the same
KR20210005646A (ko)	2018-04-26	2021-01-14	아게누스 인코포레이티드	열쇼크 단백질-결합 펩티드 조성물 및 그의 이용 방법
GB201901608D0 (en)	2019-02-06	2019-03-27	Vib Vzw	Vaccine adjuvant conjugates
KR20220053007A (ko)	2019-08-30	2022-04-28	아게누스 인코포레이티드	항-cd96 항체 및 이의 사용 방법
AU2020403296B2 (en) *	2019-12-13	2025-03-06	Grand Theravac Life Science (Nanjing) Co., Ltd.	Immunostimulatory composition and use thereof
CN113058033B (zh) *	2019-12-16	2024-07-09	远大赛威信生命科学(南京)有限公司	一种用于预防和治疗乙型肝炎的药物组合物及其用途
AU2021321944A1 (en)	2020-08-07	2023-04-06	Access To Advanced Health Institute	Purified saponins and chromatographic process for purification of same
EP4326237A4 (en) *	2021-04-23	2025-02-26	Flow Pharma Inc.	Microsphere formulations comprising multiple non-identical peptides and methods for making the same

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4469863A (en)	1980-11-12	1984-09-04	Ts O Paul O P	Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5023243A (en)	1981-10-23	1991-06-11	Molecular Biosystems, Inc.	Oligonucleotide therapeutic agent and method of making same
US4522811A (en)	1982-07-08	1985-06-11	Syntex (U.S.A.) Inc.	Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5352449A (en)	1986-05-30	1994-10-04	Cambridge Biotech Corporation	Vaccine comprising recombinant feline leukemia antigen and saponin adjuvant
US5583112A (en)	1987-05-29	1996-12-10	Cambridge Biotech Corporation	Saponin-antigen conjugates and the use thereof
US5057540A (en)	1987-05-29	1991-10-15	Cambridge Biotech Corporation	Saponin adjuvant
US5650398A (en)	1992-07-02	1997-07-22	Cambridge Biotech Corporation	Drug delivery enhancement via modified saponins
US5273965A (en)	1992-07-02	1993-12-28	Cambridge Biotech Corporation	Methods for enhancing drug delivery with modified saponins
CA2172153C (en) *	1993-09-20	2010-03-09	John C. Reed	Regulation of bcl-2 gene expression
WO1995026204A1 (en)	1994-03-25	1995-10-05	Isis Pharmaceuticals, Inc.	Immune stimulation by phosphorothioate oligonucleotide analogs
WO1996002555A1 (en) *	1994-07-15	1996-02-01	The University Of Iowa Research Foundation	Immunomodulatory oligonucleotides
US6429199B1 (en) *	1994-07-15	2002-08-06	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en) *	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US6239116B1 (en) *	1994-07-15	2001-05-29	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
AUPM873294A0 (en)	1994-10-12	1994-11-03	Csl Limited	Saponin preparations and use thereof in iscoms
US6335018B1 (en) *	1995-05-01	2002-01-01	Aventis Pasteur Limited	High molecular weight major outer membrane protein of moraxella
US5968909A (en) *	1995-08-04	1999-10-19	Hybridon, Inc.	Method of modulating gene expression with reduced immunostimulatory response
US6231859B1 (en)	1996-12-02	2001-05-15	Aquila Biopharmaceuticals, Inc.	Saponin adjuvant compositions
WO1998037919A1 (en)	1997-02-28	1998-09-03	University Of Iowa Research Foundation	USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
US6406705B1 (en)	1997-03-10	2002-06-18	University Of Iowa Research Foundation	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
AU753688B2 (en)	1997-03-10	2002-10-24	Ottawa Civic Loeb Research Institute	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
WO1998052573A1 (en)	1997-05-20	1998-11-26	Galenica Pharmaceuticals, Inc.	Triterpene saponin analogs having adjuvant and immunostimulatory activity
AU7690898A (en) *	1997-05-20	1998-12-11	Ottawa Civic Hospital Loeb Research Institute	Vectors and methods for immunization or therapeutic protocols
WO1998055495A2 (en)	1997-06-06	1998-12-10	Dynavax Technologies Corporation	Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
CA2654522C (en)	1997-08-29	2014-01-28	Antigenics Inc.	Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as exipient
US6013258A (en) *	1997-10-09	2000-01-11	Zycos Inc.	Immunogenic peptides from the HPV E7 protein
US6218371B1 (en) *	1998-04-03	2001-04-17	University Of Iowa Research Foundation	Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
WO1999058118A2 (en)	1998-05-14	1999-11-18	Cpg Immunopharmaceuticals Gmbh	METHODS FOR REGULATING HEMATOPOIESIS USING CpG-OLIGONUCLEOTIDES
DK1733735T3 (da) *	1998-05-22	2017-06-19	Ottawa Hospital Res Inst	Fremgangsmåder og produkter til induktion af mukosal immunitet
US6562798B1 (en)	1998-06-05	2003-05-13	Dynavax Technologies Corp.	Immunostimulatory oligonucleotides with modified bases and methods of use thereof
EP1104306B1 (en) *	1998-08-10	2006-01-11	Antigenics Inc.	Compositions of cpg and saponin adjuvants and methods of use thereof
US20010034330A1 (en)	1998-08-10	2001-10-25	Charlotte Kensil	Innate immunity-stimulating compositions of CpG and saponin and methods thereof
WO2000021556A1 (en)	1998-10-09	2000-04-20	Dynavax Technologies Corporation	Anti hiv compositions comprising immunostimulatory polynucleotides and hiv antigens
CN1227030C (zh)	1999-04-19	2005-11-16	史密丝克莱恩比彻姆生物有限公司	包含皂甙和免疫刺激寡核苷酸的佐剂组合物
US6558670B1 (en)	1999-04-19	2003-05-06	Smithkline Beechman Biologicals S.A.	Vaccine adjuvants
HU229642B1 (en)	2000-10-18	2014-03-28	Glaxosmithkline Beecham Biolog S A	Vaccines against cancers
US20030119774A1 (en) *	2001-09-25	2003-06-26	Marianna Foldvari	Compositions and methods for stimulating an immune response
AR045702A1 (es) *	2001-10-03	2005-11-09	Chiron Corp	Composiciones de adyuvantes.
JP2005508945A (ja) *	2001-10-06	2005-04-07	メリアルリミテッド	Ｃｐｇ配合物及び関連方法
SE0301998D0 (sv) *	2003-07-07	2003-07-07	Isconova Ab	Quil A fraction with low toxicity and use thereof
GB0401239D0 (en) *	2004-01-21	2004-02-25	Molecularnature Ltd	Adjuvant compositions

1999
- 1999-08-06 EP EP99939711A patent/EP1104306B1/en not_active Expired - Lifetime
- 1999-08-06 JP JP2000564661A patent/JP4620251B2/ja not_active Expired - Lifetime
- 1999-08-06 CA CA2340174A patent/CA2340174C/en not_active Expired - Lifetime
- 1999-08-06 AU AU53953/99A patent/AU773204C/en not_active Expired
- 1999-08-06 PT PT99939711T patent/PT1104306E/pt unknown
- 1999-08-06 WO PCT/US1999/017956 patent/WO2000009159A1/en not_active Ceased
- 1999-08-06 ES ES99939711T patent/ES2257068T3/es not_active Expired - Lifetime
- 1999-08-06 DK DK99939711T patent/DK1104306T3/da active
- 1999-08-06 US US09/369,941 patent/US7049302B1/en not_active Expired - Lifetime
- 1999-08-06 AT AT99939711T patent/ATE315405T1/de active
- 1999-08-06 DE DE69929444T patent/DE69929444T2/de not_active Expired - Lifetime
2006
- 2006-03-10 US US11/373,806 patent/US7858589B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP1104306B1 (en)	2006-01-11
DE69929444T2 (de)	2006-09-28
US7858589B2 (en)	2010-12-28
AU773204B2 (en)	2004-05-20
US20060177458A1 (en)	2006-08-10
PT1104306E (pt)	2006-05-31
WO2000009159A9 (en)	2000-07-27
JP4620251B2 (ja)	2011-01-26
CA2340174C (en)	2011-01-04
AU5395399A (en)	2000-03-06
EP1104306A1 (en)	2001-06-06
AU773204C (en)	2005-05-19
DE69929444D1 (de)	2006-04-06
US7049302B1 (en)	2006-05-23
JP2002522510A (ja)	2002-07-23
ATE315405T1 (de)	2006-02-15
CA2340174A1 (en)	2000-02-24
ES2257068T3 (es)	2006-07-16
WO2000009159A1 (en)	2000-02-24

Publication	Publication Date	Title
PT1104306E (pt)	2006-05-31	Composicoes de cpg e adjuvantes de saponina e seus metodos
IS4518A (is)	1999-01-10	Nýtt lyfjaform fyrir bóluefni
MY125202A (en)	2006-07-31	Vaccine
EP1594536A4 (en)	2006-09-06	ADJUVANT INFLUENZA VACCINE
GB0123580D0 (en)	2001-11-21	Vaccine
DK1459766T3 (da)	2008-10-13	Adjuvanssammensætninger til forstærkning af immunresponser på polynukleotidbaserede vacciner
NO20015073D0 (no)	2001-10-18	Vaksiner
PT865297E (pt)	2003-03-31	Composicoes de vacinas para administracao intranasal compreendendo quitosano e suas utilizacoes
MXPA01007760A (es)	2003-06-24	Compuesto adyuvante inmunologico.
WO2004030608A3 (en)	2005-03-10	Nanoemulsion vaccines
IL150602A (en)	2010-12-30	Proteosome influenza vaccine, method for preparing such and use thereof
MY125000A (en)	2006-07-31	Novel compositions
AU5162201A (en)	2001-10-30	Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and qs-21
GB2386072A (en)	2003-09-10	Novel vaccine
CY1112658T1 (el)	2016-02-10	Εμβολια τα οποια περιεχουν αντιγονο μαgε συνδεομενο με θραυσμα πρωτεϊνης d
ATE392216T1 (de)	2008-05-15	Mycobakterieller impfstoff
ATE370745T1 (de)	2007-09-15	Verbesserte polysaccharid- und glykokonjugat- vakzine
AU2001284354A1 (en)	2002-02-13	Immunological adjuvant compounds, compositions, and methods of use thereof
WO2000050073A3 (en)	2001-02-22	Caulobacter lps immunoadjuvant
WO2000006198A3 (en)	2001-07-19	Adjuvant comprising pulmonary surfactant
WO2001015727A3 (en)	2001-09-07	Compositions of immunostimulatory polymers and saponin adjuvants and uses thereof
DE69922212D1 (de)	2004-12-30	Impfstoff enthaltend zytokin-induzierte heat shock proteine (hsp)
MY127452A (en)	2006-12-29	Vaccines.
DK0952771T3 (da)	2008-05-19	Hidtil ukendte saponinpræparater og anvendelser deraf
DK1227840T3 (da)	2008-02-04	Adjuverede, genetiske vacciner